[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY35916A - Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio - Google Patents

Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio

Info

Publication number
UY35916A
UY35916A UY0001035916A UY35916A UY35916A UY 35916 A UY35916 A UY 35916A UY 0001035916 A UY0001035916 A UY 0001035916A UY 35916 A UY35916 A UY 35916A UY 35916 A UY35916 A UY 35916A
Authority
UY
Uruguay
Prior art keywords
bromodominum
tricyclic compounds
antineoplastic agents
inhibiting
inhibiting antineoplastic
Prior art date
Application number
UY0001035916A
Other languages
English (en)
Inventor
Vaccaro Wayne
Mikkel V Debenedetto
Andrew P Degnan
Fang Haiquan
Matthew D Hill
Huang Hong
William D Schmitz
John E Starrett Jr
Wen-Ching Han
George V Delucca
Daniel O Malley
Gill Patrice
Claude A Quesnelle
Francis Y Lee
John S Tokarski
Ashvinikumar V Gavai
Derek J Norris
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35916A publication Critical patent/UY35916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a compuestos tricíclicos, composiciones aceptables desde el punto de vista farmacéutico que comprenden compuestos de la invención y métodos para usar esas composiciones en el tratamiento de diversos trastornos.
UY0001035916A 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio UY35916A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24

Publications (1)

Publication Number Publication Date
UY35916A true UY35916A (es) 2015-06-30

Family

ID=52293305

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035916A UY35916A (es) 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio

Country Status (33)

Country Link
US (1) US20160318928A1 (es)
EP (2) EP3087071B1 (es)
JP (2) JP6466456B2 (es)
KR (1) KR102457145B1 (es)
CN (2) CN108558871B (es)
AR (2) AR099379A1 (es)
AU (1) AU2014369982B2 (es)
BR (1) BR112016013744B1 (es)
CA (1) CA2934953C (es)
CL (1) CL2016001629A1 (es)
CY (2) CY1121076T1 (es)
DK (2) DK3087071T3 (es)
EA (2) EA201990240A1 (es)
ES (2) ES2698998T3 (es)
HR (2) HRP20181849T1 (es)
HU (2) HUE041719T2 (es)
IL (1) IL246359B (es)
LT (2) LT3466949T (es)
MA (1) MA39211B1 (es)
MX (1) MX369491B (es)
MY (1) MY176489A (es)
NZ (1) NZ722326A (es)
PE (1) PE20160844A1 (es)
PH (1) PH12016500953A1 (es)
PL (2) PL3087071T3 (es)
PT (2) PT3087071T (es)
RS (2) RS61479B1 (es)
SG (1) SG11201605097SA (es)
SI (2) SI3087071T1 (es)
TN (1) TN2016000238A1 (es)
TW (2) TWI736517B (es)
UY (1) UY35916A (es)
WO (1) WO2015100282A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
PL3087071T3 (pl) * 2013-12-24 2019-03-29 Bristol-Myers Squibb Company Związki tricykliczne jako środki przeciwrakowe
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
AU2015222887B2 (en) * 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
ES2770349T3 (es) 2015-05-12 2020-07-01 Bristol Myers Squibb Co Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
AU2016293674B2 (en) 2015-07-16 2019-11-21 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
MX2018003824A (es) * 2015-10-02 2019-04-01 Dana Farber Cancer Inst Inc Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control.
JP6855505B2 (ja) * 2016-01-20 2021-04-07 ニンボー ウェンダ ファーマー テクノロジー エルティーディー． ブロモドメイン阻害剤としてのカルボリン誘導体
WO2017124934A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的含膦咔啉衍生物
JP2019508494A (ja) * 2016-02-05 2019-03-28 チーア タイ ティエンチン ファーマシューティカル グループ カンパニー，リミティド ブロモドメインタンパク質阻害剤の三環式化合物、並びにその製造、医薬組成物及び使用
KR20180116372A (ko) 2016-03-01 2018-10-24 코어셉트 쎄라퓨틱스, 잉크. 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
RU2019117356A (ru) 2016-11-10 2020-12-10 Лосинь Фармасьютикал (Шанхай) Ко., Лтд. Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение
CN109824693B (zh) * 2017-04-18 2020-12-08 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
JP7168245B2 (ja) * 2018-06-25 2022-11-09 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 三環式化合物
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN113544129B (zh) * 2019-04-04 2024-07-23 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN114502534A (zh) 2019-09-30 2022-05-13 协和麒麟株式会社 Bet降解剂
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
AU2022211285A1 (en) * 2021-01-22 2023-08-17 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
AU2022227673A1 (en) * 2021-02-25 2023-08-17 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
CA3213803A1 (en) * 2021-05-06 2022-11-10 Sharon Cohen-Vered Crystalline carbazole derivative
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623125A1 (en) * 1992-01-15 1994-11-09 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
CA2542682A1 (en) 2003-10-18 2005-05-06 Bayer Healthcare Ag 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases
WO2005051318A2 (en) * 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
SI1879573T1 (sl) 2005-05-10 2013-04-30 Incyte Corporation Experimental Station Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
TWI382974B (zh) 2005-12-20 2013-01-21 Incyte Corp 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
DK4209510T5 (da) 2008-12-09 2024-07-22 Hoffmann La Roche Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
HUE049825T2 (hu) 2009-09-03 2020-10-28 Merck Sharp & Dohme Anti-GITR antitestek
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
JP5677451B2 (ja) 2009-12-10 2015-02-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用
AU2011219758A1 (en) 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having Mnkl/ Mnk2 inhibiting activity for pharmaceutical compositions
MY156358A (en) 2010-03-04 2016-02-15 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
DK2566517T3 (en) 2010-05-04 2019-01-07 Five Prime Therapeutics Inc ANTIBODIES THAT BIND CSF1R
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
EP2614082B1 (en) 2010-09-09 2018-10-03 Pfizer Inc 4-1bb binding molecules
PT2651951E (pt) * 2010-12-16 2015-01-14 Hoffmann La Roche Compostos tricíclicos do inibidor pi3k e processos para a sua utilização
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (es) 2011-04-15 2018-03-17
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
KR20140068883A (ko) * 2011-09-28 2014-06-09 이데미쓰 고산 가부시키가이샤 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
KR20140113683A (ko) 2011-12-15 2014-09-24 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
JP6416630B2 (ja) 2012-02-06 2018-10-31 ジェネンテック， インコーポレイテッド Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015517490A (ja) 2012-05-11 2015-06-22 ファイブ プライム セラピューティックス インコーポレイテッド コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP2890398A4 (en) 2012-08-31 2016-03-09 Five Prime Therapeutics Inc METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R)
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105189488B (zh) * 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
WO2014164596A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
PL3087071T3 (pl) * 2013-12-24 2019-03-29 Bristol-Myers Squibb Company Związki tricykliczne jako środki przeciwrakowe

Also Published As

Publication number Publication date
IL246359B (en) 2020-04-30
JP2017505762A (ja) 2017-02-23
US20160318928A1 (en) 2016-11-03
HRP20210212T8 (hr) 2021-08-20
IL246359A0 (en) 2016-08-31
TW201609725A (zh) 2016-03-16
LT3466949T (lt) 2021-03-25
ES2857848T3 (es) 2021-09-29
BR112016013744B1 (pt) 2022-08-30
TW202028203A (zh) 2020-08-01
SI3087071T1 (sl) 2018-11-30
TWI726544B (zh) 2021-05-01
JP6675501B2 (ja) 2020-04-01
EP3466949A1 (en) 2019-04-10
SI3466949T1 (sl) 2021-03-31
MY176489A (en) 2020-08-12
CY1124061T1 (el) 2022-05-27
KR20160095168A (ko) 2016-08-10
EP3087071B1 (en) 2018-09-05
MA39211B1 (fr) 2019-01-31
PT3466949T (pt) 2021-02-25
AR099379A1 (es) 2016-07-20
PL3087071T3 (pl) 2019-03-29
AU2014369982B2 (en) 2019-04-18
AU2014369982A1 (en) 2016-08-04
EA032469B1 (ru) 2019-05-31
TN2016000238A1 (en) 2017-10-06
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
RS61479B1 (sr) 2021-03-31
MX2016007928A (es) 2016-08-03
KR102457145B1 (ko) 2022-10-19
JP2019070014A (ja) 2019-05-09
HUE041719T2 (hu) 2019-05-28
EA201990240A1 (ru) 2019-06-28
CN108558871B (zh) 2022-02-18
CN106029663B (zh) 2018-06-01
EP3466949B1 (en) 2020-12-23
PL3466949T3 (pl) 2021-05-31
HRP20210212T1 (hr) 2021-07-09
CY1121076T1 (el) 2019-12-11
MX369491B (es) 2019-11-11
DK3087071T3 (da) 2019-01-02
PH12016500953A1 (en) 2016-06-27
CA2934953C (en) 2022-09-20
CN106029663A (zh) 2016-10-12
PE20160844A1 (es) 2016-09-03
EA201691070A1 (ru) 2016-11-30
PT3087071T (pt) 2018-11-29
WO2015100282A1 (en) 2015-07-02
AR123996A2 (es) 2023-02-01
ES2698998T3 (es) 2019-02-06
RS58014B1 (sr) 2019-02-28
JP6466456B2 (ja) 2019-02-06
DK3466949T3 (da) 2021-03-15
HUE054183T2 (hu) 2021-08-30
HRP20181849T1 (hr) 2018-12-28
SG11201605097SA (en) 2016-07-28
CA2934953A1 (en) 2015-07-02
EP3087071A1 (en) 2016-11-02
CN108558871A (zh) 2018-09-21
BR112016013744A2 (es) 2017-10-03
CL2016001629A1 (es) 2017-02-17
NZ722326A (en) 2019-09-27
TWI736517B (zh) 2021-08-21

Similar Documents

Publication Publication Date Title
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
NI201500140A (es) Compuestos y composiciones terapéuticos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UY36075A (es) Derivados de tubulisina
NI201500112A (es) Compuestos de azabencimidazol como inhibidores de isozimas pde4 para el tratamiento del snc y otros trastornos.
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
CL2015002897A1 (es) Inhibidores de bace1
DOP2017000107A (es) Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos
GT201500247A (es) Imidazopiridazinas sustituidas
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas